Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion
- PMID: 26200610
- PMCID: PMC4603013
- DOI: 10.1097/MD.0000000000001010
Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion
Abstract
We investigated the role of F-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) for the differential diagnosis of malignant and benign pleural effusion. We studied 36 consecutive patients with histologically proven cancer (excluding malignant mesothelioma) who underwent FDG-PET/CT for suspected malignant pleural effusion. Fourteen patients had cytologically proven malignant pleural effusion and the other 22 patients had either negative cytology or clinical follow-up, which confirmed the benign etiology. We examined the maximum standardized uptake values (SUV max) of pleural effusion and the target-to-normal tissue ratio (TNR), calculated as the ratio of the pleural effusion SUV max to the SUV mean of the normal tissues (liver, spleen, 12th thoracic vertebrae [Th12], thoracic aorta, and spinalis muscle). We also examined the size and density (in Hounsfield units) of the pleural effusion and pleural abnormalities on CT images. TNR (Th12) and increased pleural FDG uptake compared to background blood pool were significantly more frequent in cases with malignant pleural effusion (P < 0.05 for both). The cutoff TNR (Th12) value of >0.95 was the most accurate; the sensitivity, specificity, and accuracy for this value were 93%, 68%, and 75%, respectively. FDG-PET/CT can be a useful method for the differential diagnosis of malignant and benign pleural effusion.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures

Similar articles
-
Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.J Thorac Oncol. 2009 Dec;4(12):1480-4. doi: 10.1097/JTO.0b013e3181c0a7ff. J Thorac Oncol. 2009. PMID: 19875971
-
Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients.Onkologie. 2011;34(6):298-303. doi: 10.1159/000328793. Epub 2011 May 20. Onkologie. 2011. PMID: 21625182
-
The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.PLoS One. 2016 Aug 25;11(8):e0161764. doi: 10.1371/journal.pone.0161764. eCollection 2016. PLoS One. 2016. PMID: 27560933 Free PMC article.
-
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?Interact Cardiovasc Thorac Surg. 2011 May;12(5):806-11. doi: 10.1510/icvts.2010.255901. Epub 2011 Jan 25. Interact Cardiovasc Thorac Surg. 2011. PMID: 21266493 Review.
-
[18-Fluoro-deoxy-glucose (15FDG) positon emission tomography (PET) for the evaluation of malignant pleural disease].Rev Pneumol Clin. 2006 Apr;62(2):128-34. doi: 10.1016/s0761-8417(06)75427-x. Rev Pneumol Clin. 2006. PMID: 16670667 Review. French.
Cited by
-
PleThora: Pleural effusion and thoracic cavity segmentations in diseased lungs for benchmarking chest CT processing pipelines.Med Phys. 2020 Nov;47(11):5941-5952. doi: 10.1002/mp.14424. Epub 2020 Aug 28. Med Phys. 2020. PMID: 32749075 Free PMC article.
-
Pleural Uptake Patterns in F18Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Scans Improve the Identification of Malignant Pleural Effusions.J Clin Med. 2023 Nov 8;12(22):6977. doi: 10.3390/jcm12226977. J Clin Med. 2023. PMID: 38002592 Free PMC article.
-
Comment on: "the FDG PET/CT score" for the diagnosis of malignant pleural effusion.Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):5-6. doi: 10.1007/s00259-019-04512-3. Epub 2019 Sep 4. Eur J Nucl Med Mol Imaging. 2020. PMID: 31485682 No abstract available.
-
Predicting the nature of pleural effusion in patients with lung adenocarcinoma based on 18F-FDG PET/CT.EJNMMI Res. 2021 Oct 15;11(1):108. doi: 10.1186/s13550-021-00850-2. EJNMMI Res. 2021. PMID: 34652524 Free PMC article.
-
Developing a Prediction Score for the Diagnosis of Malignant Pleural Effusion: MPE Score.Asian Pac J Cancer Prev. 2022 Jan 1;23(1):25-31. doi: 10.31557/APJCP.2022.23.1.25. Asian Pac J Cancer Prev. 2022. PMID: 35092368 Free PMC article.
References
-
- Toaff JS, Metser U, Gottfried M, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomography-computed tomography. Invest Radiol 2005; 40:204–209. - PubMed
-
- Kim BS, Kim IJ, Kim SJ, et al. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients. Onkologie 2011; 34:298–303. - PubMed
-
- Alkhawaldeh K, Biersack HJ, Henke A, et al. Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. Clin Nucl Med 2011; 36:423–428. - PubMed
-
- Letovanec I, Allenbach G, Mihaescu A, et al. 18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer. A cytopathological correlation. Nuklearmedizin 2012; 51:186–193. - PubMed